3016: How Creyon Bio is Using AI to Transform Drug Development
In this episode, I have an insightful conversation with Chris Hart, the CEO of Creyon Bio, to dive into how artificial intelligence is reshaping drug development. Creyon Bio is pioneering the use of AI to engineer Oligonucleotide-Based Medicines (OBMs), prioritizing safety in their approach to creating effective treatments. By applying cutting-edge technology, the company is able to streamline the identification of safe medicines, offering a more efficient path to drug discovery. One of the most compelling examples of their work is the recent treatment of a baby boy diagnosed with an…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.